257. Hepatic glycogenosis Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 14 / Drugs : 27 - (DrugBank : 7) / Drug target genes : 3 - Drug target pathways : 8
Hepatic glycogenosis and other diseases between which drug repositioning (DR) might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Score (Drug repositionability)
| ID | Diseases (Sorted by score) | Score |
|---|---|---|
| 257 | Hepatic glycogenosis | - |
| 6 | Parkinson disease | 2.000 |
| 19 | Lysosomal storage disease | 2.000 |
| 46 | Malignant rheumatoid arthritis | 2.000 |
| 49 | Systemic lupus erythematosus | 2.000 |
| 66 | IgA nephropathy | 2.000 |
| 86 | Pulmonary arterial hypertension | 2.000 |
| 96 | Crohn disease | 2.000 |
| 222 | Primary nephrotic syndrome | 2.000 |
| 271 | Ankylosing spondylitis | 2.000 |
| 113 | Muscular dystrophy | 2.000 |
| 93 | Primary biliary cholangitis | 2.000 |
| 107 | Juvenile idiopathic arthritis | 2.000 |
| 97 | Ulcerative colitis | 2.000 |
| 224 | Purpura nephritis | 2.000 |
| 220 | Rapidly progressive glomerulonephritis | 1.000 |
| 30 | Distal myopathy | 1.000 |